Vivos Extends IsoPet Trademark Protection
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Vivos Extends IsoPet Trademark Protection

Pharma Tech Outlook | Friday, June 04, 2021

The mark has been registered by WIPO, which has published it in the WIPO Gazette of International Marks and provided us a certificate of registration.

FREMONT, CA: Vivos, a pharmaceutical company, had previously filed to extend the protection of its IsoPet trademark globally. The firm announced that the Commissioner for Trademarks at the U.S. Patent and Trademark Office has approved the filing and Certification of the IsoPet Madrid Protocol international application for employment in connection with Isotopes for veterinary use; radio-isotope markers for therapeutic veterinary purposes in Class 5.

The World Intellectual Property Organization’s (WIPO) International Bureau assessed the international application and decided to comply with the Madrid Protocol filing criteria. The mark has been registered by WIPO, which has published it in the WIPO Gazette of International Marks and provided us a certificate of registration.

Within 18 months of the international registration date, each country indicated in the registration (Australia, Brazil, Canada, European Union, Japan, Korea, Russia, and the United Kingdom) has the right to object to the registration being extended to its country.

Michael K. Korenko, President and CEO of Vivosstated, “The expansion of our trademark protection internationally is an important development given the increasing international interest in our Isopet therapy and supports our mission to create a leading global brand for the treatment of tumors in pets through our Isopet global licensing initiative.”

Weekly Brief

Read Also